All the right boxes just keep getting ticked for the unique CAVATAK which has been developed for melanoma, prostate, and now the most topical one at the moment - breast cancer
The first intravenous delivery of CAVATAK (which is anticipated to be a substantially more potent system)passes safety monitoring -intratumoural delivery passed safety commitee last year
FDA has granted Viralytics orphan drug status for CAVATAK
Viralytics investment in CBIO to provide $ windfall as CBIO has now signed agreement with Novo Nordisk
USA patent issued
European patent office issued notice of allowance
Hasselhurst has been recommending VLA as a buy in Money and Bulletin magazines
VLA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
